PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration
Systematic Reviews volume 9, Article number: 247 (2020)
Moxibustion is a common intervention of Chinese medicine (CM). Systematic reviews (SRs) on moxibustion are increasing. Although the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement provides guidelines for SRs, the quality of moxibustion-related SRs is still not satisfactory. In particular, descriptions of the interventions and the rationale for using moxibustion are insufficient. To address these inadequacies, the working group developed this PRISMA extension for reporting SRs of moxibustion (PRISMA-M 2020).
A group of CM clinical professionals, methodologists of SRs, reporting guideline developers, and journal editors developed this PRISMA-M 2020 through a comprehensive process that includes registration, literature review, consensus meetings, Delphi exercises for soliciting comments, and revision, resulting in this final draft.
Seven of the 27 PRISMA checklist items, namely title (1), rationale (3), eligibility criteria (6), data item (11), additional analyses (16), study characteristics (18), and additional analysis (23), were extended, with specific reference to the application of moxibustion. Illustrative examples and explanations for each item are provided.
The PRISMA-M 2020 will help improve the reporting quality of SRs with moxibustion.
Systematic review registration
We have registered it on the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) network, particularly under the item of PRISMA-TCM: http://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/#65.
Moxibustion is a traditional therapeutic technique in which hot or burning moxa is applied on acupoints or meridians . The earliest record of moxibustion is on the oracle bones, demonstrating that moxibustion had occurred in the Yin dynasty (1600–1046 BC) . According to relics excavated from the Mawangdui tomb and Hantanpo tomb, moxibustion was used to treat many diseases and had a general application in the Qin and Han dynasties (221 BC–220 AD) in China . In the practice of Chinese medicine (CM), moxibustion is a valuable and unique type of CM intervention. With the functions of warming the meridians, promoting a smooth flow of Qi and blood, relieving the obstruction of collateral vessels, and regulating the zang-fu organs, moxibustion has been used to treat and prevent diseases, as well as maintain health and well-being for more than 2500 years [4,5,6]. Nowadays, the practice of moxibustion has been, and continues to be, widely used in Asia (mainly in China, Japan, Korea), and its use is increasing in North America and Europe [7, 8].
With more and more randomized controlled trials (RCTs) and systematic reviews (SRs) of moxibustion published every year, the importance of improving the reporting quality of moxibustion studies has been highlighted by both researchers and users of moxibustion evidence [9,10,11]. In 2013, our research group developed the STandards for Reporting Interventions in Clinical Trials Of Moxibustion (STRICTOM) , as an extension of the Consolidated Standards of Reporting Trials (CONSORT) . Some scholars have noted that the reporting quality of clinical trials of moxibustion improved after the implementation of STRICTOM [14, 15]. However, no specific reporting guidelines for moxibustion SRs have been developed, although the PRISMA statement has been published for many years , and several extensions, such as PRISMA for Abstracts , Protocols , Harms , and Complex Interventions , have been developed.
Recently, the quality of reporting of SRs with various CM interventions has raised concern, and relevant guidelines have been developed, such as PRISMA for acupuncture  and PRISMA for Chinese herbal medicines . These extensions highlight how intervention details and the CM-based rationale of why the interventions were selected, such as “treatment based on pattern differentiation,” should be reported. Although PRISMA provides the general reporting requirements of “Rationale” and “Intervention” items for all types of SRs, relevant item extensions are needed for specific types of CM SRs because each CM intervention has unique characteristics that must be considered in order to provide high-quality evidence for clinical practice.
Given this situation, we suspected that the practices of moxibustion were not being adequately reported, despite PRISMA guidelines. Aiming to determine if this were true, we conducted a preliminary literature review of 97 moxibustion SRs from 2011 to 2019. In the results, 84.5% (82/97) SRs studied CM-based moxibustion interventions and published the results in Chinese journals. For the reporting of intervention technique, 69.1% (67/97) SRs did not provide the specific type of moxibustion; 39.2% (38/97) lacked details regarding the materials, procedure, and technique used for moxibustion; 67.0% (65/97) did not fully report the selection of acupoints for moxibustion; and 28.9% (28/97) did not provide the number or duration of treatment sessions . Given such inadequate reporting, readers cannot assess the data synthesis nor the conclusions of these SRs. Such a situation undermines the value, use, and development of moxibustion therapy in modern medical practice. To address this inadequacy, our working group therefore developed a reporting extension for SRs with moxibustion based on the PRISMA checklist.
The PRISMA-M 2020 is based on the PRISMA statement. The methodology framework recommended by the EQUATOR Network was used in developing it , in the following seven steps:
This PRISMA-M was included in the registered item of “PRISMA-TCM” on the EQUATOR Network, as moxibustion is a common and important type of traditional Chinese medicine .
Authors XZ, S-YL, Q-YA, and RT conducted a literature review to assess the reporting quality of moxibustion SRs and continued to update the included articles until 31 December 2019 (Additional file 1: S1). The results of this review guided the preliminary drafting of the items ultimately included in the extension .
Authors XZ, ZX-B, and TX-W extracted the initial PRISMA items that needed extension or modification according to the characteristics of moxibustion SRs. Further, the working group members (see author list) reviewed all potential items and formulated a reporting checklist on 15 June 2017.
A total of eleven professionals, including five senior TCM practitioners, three evidence-based medicine and clinical trial methodology experts, two reporting guideline developers, and one epidemiologist, were invited to attend a face-to-face meeting in Lanzhou, China, on 19 July 2017. During the meeting, the aim and scope of the guideline with a drafted checklist were presented to the participants, followed by a discussion and revision of each proposed item. Finally, a checklist questionnaire was formed for a Delphi survey for further solicitation of comments.
Three rounds of an e-mail-based Delphi survey were conducted from November 2017 to April 2018. Thirty-five experts with rich experience in moxibustion practice, performing SRs, and developing reporting guidelines were invited. The invitation letters, which included an introduction to the study, workflow of Delphi surveys, and relevant questionnaire, were sent out; positive responses confirmed their participation. Each of the 35 individuals completed at least two rounds of the Delphi survey. The questionnaires of each round were sent to the participants from a specific email address, which was managed by one member (RT) of the working group. Anonymity and confidentiality of responses were ensured.
During the Delphi process, participants were asked to rate each item on a scale of 1 (not important) to 5 (very important), to suggest new items, and to provide comments; any items that did not reach consensus (e.g., score < 75%) and any new items were circulated in subsequent rounds. Following each round, the score for each item was calculated with the formula 100% × (1 × N5 + 0.75 × N4 + 0.5 × N3 + 0.25 × N2)/(N5 + N4 + N3 + N2 + N1), where Ni represents the number of respondents who chose specific i in the scale of “1 to 5.” Items with a score greater than or equal to 75%, namely reach a consensus, were included . This calculation formula was referred to the RIGHT (A Reporting Tool for Practice Guidelines in Health Care) statement, where both the consensus level and the weight of responses were considered . The analyses of the included items were managed by authors RT, XZ, and ZX-B.
Explanation and elaboration preparation
Explanation and elaboration (E&E) documents were prepared for each included item. Examples of good reporting were identified and edited for inclusion (e.g., citations or web addresses were removed; abbreviations were spelled out). Explanation documents were also developed to provide the rationale and describe the characteristics of moxibustion SRs.
Revision and finalization
The manuscript of this guideline was drafted by authors ZX-B and XZ. The working group members reviewed and provided revisions. The draft was also presented by team leaders in academic workshops and conferences to solicit broad comments for improvement . The manuscript, including recommendations and E&E, was finalized in May 2020.
Highlights of PRISMA-M 2020
PRISMA-M 2020 expands sections of PRISMA to ensure that the unique characteristics of moxibustion are adequately reported in SRs, so as to ensure that the data and results are accurate and complete, and that the study is reproducible. Also, the key concept of CM pattern (Table 1) is highlighted in the practice of moxibustion. Specifically, PRISMA-M 2020 elaborates on 7 of 27 PRISMA original items, namely title (1), rationale (3), eligibility criteria (6), data items (11), additional analyses (16), study characteristics (18), and additional analysis (23). The items from the STRICTOM  and Template for Intervention Description and Replication (TIDieR)  are also included, especially for the details of moxibustion intervention. The PRISMA-M 2020 checklist is presented in Table 2; extensions for moxibustion are italicized. Explanations of corresponding items are given below, and available reporting examples are provided in Additional file 1: S2. There is no modification of the PRISMA flow diagram.
Aim and scope of PRISMA-M 2020
The aim of PRISMA-M 2020 is to optimize the reporting of SRs focusing on moxibustion interventions for specific conditions and/or patterns (if any). We consider most of the PRISMA items relevant in reporting SRs assessing the benefits and harms of specific moxibustion treatments. Further, we emphasized the concept of CM pattern (if applicable) since the moxibustion prescription in CM clinical practice can be determined on pattern identification. However, we recognize that authors who address the research question without pattern contents and/or no pattern-related indicators in the primary studies may not need to focus on pattern-related extension items for the SRs. To maximize the clarity of this checklist, examples and explanations are provided for each item. For certain thematic concepts (e.g., pattern differentiation), a comprehensive description is presented in Table 1. We believe this PRISMA-M 2020 checklist will be a valuable tool for the authors and users of SRs of moxibustion.
Explanations of PRISMA-M 2020 items
Item 1: Title
PRISMA item: Identify the report as a systematic review, meta-analysis, or both.
Extension: 1a. Statement of the specific type of moxibustion treatment, such as direct moxibustion or heat-sensitive moxibustion. 1b. Statement of whether the review targets the (1) Western medicine–defined disease(s), or (2) Western medicine–defined disease(s) with specific CM pattern(s), or (3) CM pattern(s), if applicable.
Explanation. For SRs, a self-explanatory title including the PICOS (participants, interventions, comparators, outcomes, and study design) can make vital information easily accessible to readers. If the review investigates the effect of a specific type of moxibustion on a particular condition, it should be stated in the title. There are different types of moxibustion regarding the materials used and the details of procedures, such as moxa cone moxibustion, warming needle moxibustion, natural moxibustion, and heat-sensitive moxibustion . Authors are strongly encouraged to use and provide standard terminologies of moxibustion released by the World Health Organization (WHO) or International Organization for Standardization (ISO) [34, 35]. If an SR aims to target a large category of moxibustion, it is better to point this out in the title and to report, in detail, the types of moxibustion in the Abstract.
Whether the moxibustion targets a Western medicine–defined disease and/or specific pattern(s) should be clarified in the title. Readers can then easily understand which conditions are studied in the SR, and the results will be more easily applied in clinical practice. In terms of reporting the pattern names, authors are encouraged to provide the specific name if one type of pattern that will be targeted, such as “primary dysmenorrhea with cold coagulation and blood stasis syndrome”  and “prostatitis (hot and humid stasis syndrome)” . If an SR includes a broad category of patterns (e.g., more than two types of pattern), it is better to use a generalized term in the title , such as “Patterns,” “Pattern-based,” and “Pattern identification.”
Item 3: Rationale
PRISMA item: Describe the rationale for the review in the context of what is already known.
Extension: Describe the rationale for what is already known about moxibustion utilized for the target disease and/or CM pattern (if any). If applicable, relevant theory of CM should be included.
Explanation. CM has long been thought to be a kind of personalized medicine, and its unique characteristic is pattern differentiation [30, 31]. In actual clinical practice, Pattern diagnosis can help the practitioner determine a treatment principle and methods of moxibustion therapy, including the selection of acupoints, types, materials, and techniques . For example, the treatment principles of moxibustion used for excessive syndrome and deficiency syndrome are very different. Similar to CM theory, other traditional medicine systems, such as Korean medicine, also emphasize individuality during moxibustion treatment . Therefore, for moxibustion SRs, it is necessary to provide relevant CM (or other traditional medicine) theories in the description of studied disease(s)/pattern(s) and intervention(s). It is also recommended to include any medical rationale as to “how the intervention might work” in Western scientific terms. Such information can help readers to realize the importance of the research question in the review.
Item 6: Eligibility criteria
PRISMA item: Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Extension: 6a. Describe the diagnostic criteria of the target condition in Western medicine and/or CM pattern (if any). All criteria utilized should be universally recognized, or reference(s) where detailed explanation can be found should be given. 6b. Specify the types of moxibustion to be included, such as moxa burner moxibustion, natural moxibustion, or heat-sensitive moxibustion. 6c. State whether CM-related outcome(s) were included, such as the change of degree and scope of symptoms and signs related to CM pattern, or validated pattern survey, if applicable.
Explanation. Diagnostic criteria of disease(s)/pattern(s) are important to clarify the scope of target populations in the review. How the disease and/or pattern (if any) was diagnosed and what criteria were used for identifying participants should be comprehensively described. In addition, because moxibustion can be used both to treat disease and to improve health, the condition diagnosed should be clearly identified as either a disease or simply a less-than-optimum state of health. Generally, authors should choose nationally or internationally recognized diagnostic criteria and then include the eligible primary studies. However, there may be different diagnostic criteria for one pattern as established by different original trials . Thus, specific eligibility criteria for the SR should be clearly pre-designed and comprehensively described if the pattern will be involved in participant selection.
The effects of different types of moxibustion can differ. Because of this, authors should pre-define the inclusion criteria for the studied intervention. If a specific type of moxibustion will be performed, it is suggested that authors should report eligibility criteria with standard terms and definitions (if necessary), materials, procedures, and techniques. If a broad type of moxibustion will be included, authors should pre-list its scope in as much detail as possible. Additionally, moxibustion is sometimes combined with other therapies, such as acupuncture, herbs, or cupping. Thus, where applicable, authors of SRs should pre-define the selection scope and criteria for complex interventions using information from original trials.
For clinical trials testing the efficacy of moxibustion, the outcomes can usually be categorized into Western medicine–specific outcomes and CM-specific outcomes. Therefore, if an SR will include CM-related outcome(s) as eligibility criteria, the requirements for measurements and time points should be specified, because one pattern-outcome may have been assessed with different measurements in different studies .
Item 11: Data items
PRISMA item: List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Extension: 11a. List and define the data of CM pattern(s) in detail, considering the inclusion and exclusion criteria, if applicable. 11b. List and define the data of moxibustion interventions and controls (e.g., sham moxibustion), give details referring to STRICTOM and TIDieR. 11c. List and define the data of CM pattern outcome(s), considering the methods and timepoints, if applicable.
Explanation. If the CM patterns were involved in selecting participants, information on how the pattern was diagnosed and what criteria were used for inclusion and exclusion should be reported in detail. If applicable, other information, such as numbers in different patterns groups, should be included in the data. If pattern-related outcomes are assessed, it is recommended to use symptoms and signs that can be measured objectively, such as in terms of occurrence (e.g., presence or absence of symptoms or signs), by a rating scale (e.g., score assessment), or an assessment questionnaire (e.g., validated pattern survey) [43, 44]. In this way, pattern measurements used in different trials can be more readily compared. In addition, the name(s) and procedure(s) of the method(s), supporting rationale or reference(s) (if any), and the evaluators (e.g., CM practitioners, trainers, or self-reporting of patients) should be reported.
For moxibustion, the effect is associated with several important details, such as the materials and techniques used, the acupoints and meridians selected, and the number, frequency, and duration of treatment; all of these factors can vary between diseases and/or patterns. If sham moxibustion is included, descriptions on how to assess whether “sham” was achieved should be particularly reported . To ensure accurate and transparent reporting, it is recommended that authors report these details of moxibustion according to the checklists of STRICTOM and TIDieR guidelines [12, 29]. Although some detailed information may be recorded as “not reported” in the section of results (e.g., Item 18: Study characteristics), it is essential to pre-define all variables for data items in the section of methods.
Item 16: Additional analyses
PRISMA item: Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta regression), if done, indicating which were pre-specified.
Extension: Describe methods of subgroup analyses in terms of different types of included moxibustion interventions and/or included CM pattern participants (if applicable), if done, indicating which were pre-specified.
Explanation. Whether subgroup analysis should be conducted generally depends on the review objective and the heterogeneity of interventions and participants. Due to the characteristics of moxibustion interventions and CM patterns (if any), we suggest that authors consider at least the following factors in subgroup analyses: (1) different types and/or amounts of moxibustion, (2) different treatment frequency and/or courses, (3) different phases of diseases and/or patterns (if any), and (4) different control groups. If one specific type of moxibustion is studied in an SR, more details of the factors (e.g., different types of materials, treatment acupoints, and durations) should be considered in heterogeneity analyses. Although the information may be inadequately reported in original studies, it is important for reviewers to inform readers whether the subgroup analyses were pre-specified and the rationale.
Item 18: Study characteristics
PRISMA item: For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citation.
Extension: 18a. Present characteristics for the data of participants, which include CM pattern(s), considering (1) diagnostic criteria; (2) baseline data, if applicable. 18b. Present characteristics for the data of moxibustion intervention(s) and controls (e.g., sham moxibustion) for each study referring to STRICTOM and TIDieR. 18c. Present characteristics for the data of outcomes which include CM pattern(s), considering (1) name and measuring methods; (2) measuring timepoints and length of follow-up, if applicable.
Explanation. Results should be presented referring to the pre-designed data items (e.g., item 11). If any data item is insufficiently reported and cannot be obtained by contacting authors of the included trials, then it should be described as “not reported” in the review. For moxibustion SRs, information about the CM pattern (if any) studied and about interventions should be completely provided in the results, as this is the basis for readers’ assessment of the validity of data synthesis in the SRs . It is highly recommended that authors summarize the details of all relevant information for each included study in tables, which can be shown in the appendix or supplementary files. Such a presentation ensures that all pertinent items are reported and that missing or unclear information is also noted. If some data items outside the pre-defined items (e.g., item 11) are reported in the results, authors should explain why they were not included in those pre-defined items and should give all the relevant characteristics, especially with regard to interventions and patterns, if any.
Item 23: Additional analysis
PRISMA item: Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]).
Extension: Give results of subgroup analyses based on the different types of moxibustion
interventions and participants with CM patterns (if any), if done.
Explanation. If subgroup analyses are done, authors should give the results, even those without statistical significance, and they should state whether the items analyzed were pre-specified (see Items 16). Subgroup analyses are valuable because the different types of moxibustion and patterns (if any) are primary sources of heterogeneity across included studies ; however, it is essential to have sufficient relevant data for subgroup analysis. If any predefined subgroup analysis cannot be performed, authors should provide reasons (e.g., limited or insufficient data) to avoid selective outcome reporting bias.
SRs of moxibustion are essential for evaluating the efficacy and safety of this unique from of medical intervention; they are expected to be accurate and reliable. With the aim of improving their reporting quality, this PRISMA for moxibustion extension was specifically developed for SRs studying CM-based moxibustion, taking into account the pattern concept on the basis of clinical practice. Other moxibustion types of traditional medicine (e.g., Korean moxibustion), or non-pharmacological interventions that include moxibustion, could also use this as a basis for reporting. Generally, we expect that the main users of this guideline will be authors of SRs on moxibustion, journal editors, peer reviewers, methodologists, and clinical moxibustion practitioners.
As with other extensions, the PRISMA-M 2020 checklist should be used together with the original PRISMA checklist. To facilitate this use, Table 2 shows a combined checklist including both the extended moxibustion items and the original PRISMA items. To maximize the clarity of this checklist, explanations and elaborations are provided for each item, including rationale for extensions, moxibustion characteristics, and the necessity for reporting. In addition, each item is presented with two or more examples of good reporting, covering a wide range of moxibustion in complementary and alternative medicine (CAM), although the majority are CM-based studies. The examples were extracted from published SRs in both Chinese and international journals. It is recommended that users read all examples listed for one specific item to get a comprehensive understanding.
For better dissemination of PRISMA-M 2020, we will take the following specific steps: Firstly, we will continue to share it with clinical practitioners, researchers, peer reviewers, and journal editors through international conferences and seminars. Secondly, as we have publicly registered this guideline on the EQUATOR Network, all relevant results and publications will be updated in real time. Thirdly, we will contact relevant journals for endorsement as journals play an important role in the implementation of reporting guidelines. Finally, we will monitor the application and evaluate the effect of PRISMA-M 2020 continuously and, when necessary, update it according to users’ feedback and the latest evidence.
Although guidelines do help improve the quality of reporting, there are some limitations to this extension. Firstly, although this checklist was completed through extensive solicitation of comments from CM clinicians, methodologists, journal editors, and epidemiologists, more than half of the experts were CM professionals, which may not be international enough for other traditional medicines. In future iterations of this guideline, we will optimize it by soliciting and incorporating comments from a broader group of experts from CAM societies. Secondly, in the development of PRISMA-M 2020, we did not include a large-scale user-based survey to test the practicality of each item. As the value of a guideline ultimately depends on its use, we will collect broad feedback from potential users (e.g., authors, editors, and reviewers of SRs) and update it accordingly. Despite these limitations, the PRISMA-M 2020 guideline has value as the first consensus-based reporting recommendations for SRs on moxibustion. We hope that these recommendations will promote better reporting and influence the methodology design of SRs on moxibustion.
PRISMA-M 2020 was developed to help authors improve the reporting quality of SRs studying moxibustion interventions. The checklist can also be used to evaluate the current condition of reporting and to help journals identify moxibustion SRs of higher quality. Together, we believe this guideline will be a useful tool to promote the transparent reporting of SRs with moxibustion, thus to achieve its better use in clinical practice.
Availability of data and materials
All results data of this study are provided in the manuscript and supplementary files. Data regarding the specific experts’ comments is available from the corresponding author on receiving a reasonable request.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PRISMA-M 2020:
PRISMA Extension for Moxibustion intervention 2020
Enhancing the QUAlity and Transparency Of health Research
Randomized controlled trials
STandards for Reporting Interventions in Clinical Trials Of Moxibustion
Consolidated Standards of Reporting Trials
A Reporting Tool for Practice Guidelines in Health Care
Explanation and elaboration
Template for Intervention Description and Replication
Participants, interventions, comparators, outcomes, and study design
World Health Organization
International Organization for Standardization
Chinese herbal medicines
Complementary and alternative medicine
Lee MS, Kang JW, Ernst E. Does moxibustion work? An overview of systematic reviews. BMC Res Notes. 2010;3:284.
Li K, Zheng H, Liu ZZ. On hexagram-recorded therapies in oracle bones. Shanghai J Acupunct and Moxibustion. 2011;45(8):17-19. [Article in Chinese].
Huang C, Liang JK, Han L, Liu JT, Yu MY, Zhao BX. Moxibustion in early Chinese medicine and its relation to the origin of meridians: a study on the unearthed literatures. Evid Based Complement Altern Med. 2017; 2017: 8242136, 9 pages. https://doi.org/10.1155/2017/8242136.
Cheng X, Deng L. Chinese acupuncture and moxibustion. Beijing: Foreign Languages Press; 1987.
Sun GJ. Science of acupuncture and moxibustion. Shanghai: Shanghai Scientific and Technical Publishers. 1997. [In Chinese].
Shi XM, Zhou JZ. Shi Xue-min’s comprehensive textbook of acupuncture and moxibustion. Beijing: People’s Medical Publishing House; 2007.
Acupuncture Moxibustion.com. History of moxibustion. https://www.acupuncturemoxibustion.com/history-of-moxibustion/.
Coyle ME, Smith CA, Peat B. Cephalic version by moxibustion for breech presentation. Cochrane Database Syst Rev. 2012; Issue 5. Art. No.: CD003928. DOI: 10.1002/14651858.CD003928.pub3.
Liu JP, Xia Y. Quality appraisal of systematic reviews or meta-analysis on traditional Chinese medicine published in Chinese journals. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007;27(4):306-311. [Article in Chinese].
Xiong J, Zhu D, Chen R, Ye W. Report quality of randomized controlled trials of moxibustion for knee osteoarthritis based on CONSORT and STRICTOM. Zhongguo Zhen Jiu. 2015;35(8):835-839. [Article in Chinese].
Kim SY, Chae Y, Lee SM, Lee H, Park HJ. The effectiveness of moxibustion: an overview during 10 years. Evid Based Complement Alternat Med. 2011; 2011: 306515. DOI: https://doi.org/10.1093/ecam/nep16.
Cheng CW, Fu SF, Zhou QH, Wu TX, Shang HC, Tang XD, et al. Extending the CONSORT Statement to moxibustion. J Integr Med. 2013;11:54–63.
Schulz KF, Altman DG. Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726–32.
Deng RY, Chen RX, Xiong J. Quality assessment of randomized controlled trials involving moxibustion therapy for post-herpetic neuralgia based on CONSORT and STRICTOM. Chin J Tradit Chin Med Pharm. 2017;32(4): 1715-1718. [Article in Chinese].
Kim SY, Lee EJ, Jeon JH, Kim JH, Jung IC, Kim YI. Quality assessment of randomized controlled trials of moxibustion using STandards for Reporting Interventions in Clinical Trials of Moxibustion (STRICTOM) and risk of bias (ROB). J Acupunct Meridian Stud. 2017;10(4):261–75. https://doi.org/10.1016/j.jams.2017.05.012.
Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097.
Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10(4): e1001419.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;i157:352.
Guise JM, Butler ME, Chang C, Viswanathan M, Pigott T, Tugwell P, et al. AHRQ series on complex intervention systematic reviews-paper 6: PRISMA-CI extension statement & checklist. J Clin Epidemiol. 2017;90:43–50.
Wang X, Chen Y, Liu Y, Yao L, Estill J, Bian Z, et al. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med. 2019;19(1):208. https://doi.org/10.1186/s12906-019-2624-3.
Zhang X, Tian R, Lam WC, Yao L, Wang XQ, Cheng CW, et al. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension for Chinese herbal medicines 2020 (PRISMA-CHM 2020). Am J Chin Med. 2020;48(6):1–35. https://doi.org/10.1142/S0192415X20500639.
Tian R, Zhang X, Li SY, Aixinjueluo QY, Lam WC, Bian ZX. Reporting quality of systematic reviews with Moxibustion. Chin Med. 2020;15:104. https://doi.org/10.1186/s13020-020-00385-z.
Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7:e1000217. https://doi.org/10.1371/journal.pmed.1000217.
Enhancing the QUAlity and Transparency Of health Research (EQUAOR) Network. http://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/#65.
Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract. 2010;15(5):625–32. https://doi.org/10.1007/s10459-010-9222-y.
Chen Y, Yang K, Marušić A, Qaseem A, Meerpohl JJ, Flottorp S, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med. 2017;166:128–32. https://doi.org/10.7326/M16-1565.
Tian R, Zhao C, Cheng CW, Lam WC, Yang Z, Wu TX, et al. Constructing the Chinese medicine clinical curative effects research report system. Chin J Evid Based Med. 2018; 18(7): 651-653. [Article in Chinese].
Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;g1687([PMID: 24609605]):348. https://doi.org/10.1136/bmj.g1687.
Ma SR, Liu XR. The foundations of Chinese medicine. Beijing: China Press of Traditional Chinese Medicine; 2015. [Both in English and Chinese].
Zhang X, Tian R, Zhao C, Birch S, Lee JA, Alraek T, et al. The use of pattern differentiation in WHO-registered traditional Chinese medicine trials–a systematic review. Eur J Integr Med. 2019;30:100945. https://doi.org/10.1016/j.eujim.2019.100945.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100.
Luo MM, Wang HQ, Cheng K, Shang Y, Zhang YW. Analysis on the current situation of moxibustion. Acta Chin Med. 2019;34(258): 2319-2323. [Article in Chinese].
World Health Organization. Regional Office for the Western Pacific. WHO international standard terminologies on traditional medicine in the Western Pacific Region. Manila: WHO Regional Office for the Western Pacific; 2007. https://apps.who.int/iris/handle/10665/206952.
International Organization for Standardization. ISO/TS 16843-3:2017 Health informatics—categorial structures for representation of acupuncture—part 3: moxibustion. International Organization for Standardization (ISO). 2017; 1-15.
Yu XL, Li L. Evaluation of clinical curative effect of primary dysmenorrhea with cold coagulation and blood stasis syndrome treated with external characteristics of gynecological characteristics. Registration number: ChiCTR-IIR-17012977, Chinese Clinical Trial Registration. 2017; http://www.chictr.org.cn/showproj.aspx?proj=22204.
Yang S, Wang Y. A randomized, controlled, single blind, multi-center study of thunderbolt moxibustion treatment for prostatitis (hot and humid stasis type TCM ‘zhen). Registration number: ChiCTR-INR-16008956, Chinese Clinical Trial Registration. 2016; http://www.chictr.org.cn/com/25/showprojen.aspx?proj=14059.
He L, Qiu MY. Dialectical moxibustion treatment of uremia patients on hemodialysis with frailty syndrome. Registration number: ChiCTR-IOR-17013931, Chinese Clinical Trial Registration. 2017; http://www.chictr.org.cn/showproj.aspx?proj=23935.
Liu B. Study of the multidimensional perspectives on the theory of syndrome differentiation and treatment with acupuncture and moxibustion. Zhongguo Zhen Jiu. 2017;37 (6): 653-657. [Article in Chinese].
Kwon HJ, Kim YS. General guide for Korean acupuncture & moxibustion. Open J Immunol. 2015;5:90–103. https://doi.org/10.4236/oji.2015.53010.
Zhang ZQ, Wang YP, Zhang HM, et al., Common problems and countermeasures in standardization of traditional Chinese medicine syndrome. Modern Chin Clin Med. 2016;23 (6):1-3. [Article in Chinese].
Bian ZX, Moher D, Li YP, Wu TX, Dagenais S, Cheng CW, et al. Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao. 2008;6:771–5. https://doi.org/10.3736/jcim20080801.
Berle CA, Cobbin D, Smith N, Zaslawski C. A novel approach to evaluate traditional Chinese medicine treatment outcomes using pattern identification. J Altern Complement Med. 2010;16:357–67. https://doi.org/10.1089/acm.2009.0367.
Wang SQ, Gao Y, Wu SX. Thoughts on the clinical evaluation method of new medicine of syndrome TCM. World Chin Med. 2014; 9: 1093-1095. [Article in Chinese].
Takayama S, Takashima S, Okajima J, Watanabe M, Kamiya T, Seki T, et al. Development and clinical application of a precise temperature-control device as an alternate for conventional moxibustion therapy. Evid Based Complement Alternat Med. 2012;2012:426829. https://doi.org/10.1155/2012/426829..
Zhang X, Aixinjueluo QY, Li SY, Song LL, Lau CT, Tian R, et al. Reporting quality of Cochrane systematic reviews with Chinese herbal medicines. Syst Rev. 2019;8:302. https://doi.org/10.1186/s13643-019-1218-y.
Kim SH, Jeong JH, Lim JH, Kim BK. Acupuncture using pattern-identification for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials. Integr Med Res. 2019;8(3):216–26. https://doi.org/10.1016/j.imr.2019.08.002.
The authors thank Dr. Martha Dahlen for her critical English editing of the manuscript.
This work was supported by Fang’s Charitable Foundation and Strategic Development Fund of HKBU, Hong Kong. The funder had no role in the design of the study; in the collection, analysis, and interpretation of the data; nor in the writing of the manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhang, X., Tan, R., Lam, W.C. et al. PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration. Syst Rev 9, 247 (2020). https://doi.org/10.1186/s13643-020-01502-7